(MSI) and DNA polymerase epsilon (POLE) mutation (70%), stomach and esophageal cancer carrying MSI and POLE mutation (70%) and diffuse large B-cell lymphoma (70%). 1 Somatic mutations in various components within this pathway, including APC regulator of WNT signaling pathway (APC; previous name, adenomatous polyposis coli), β-catenin (CTNNB1), transcription factor 7 like 2 (TCF7L2), ring finger protein 43 (RNF43), R-spondin (RSPO), and AXIN1, cause its aberrant activation. In line with previous reports, 2 org/]). A high frequency of mutations in the CTNNB1 gene has also been found in pituitary (41%), soft tissue (36%), and liver tumors (21%).
In the Wnt/β-catenin signaling pathway, β-catenin is suppressed by a degradation complex consisting of APC, Axin, glycogen synthase kinase-3β, and casein kinase 1α (CK1α). However, dysfunction in any of the components of the complex or activating mutations in β-catenin itself causes abnormal accumulation of β-catenin in the cells. Translocated into the nucleus, β-catenin forms a complex with members of the T-cell factor (TCF) family of DNA-binding proteins, and consequently leads to transcriptional activation of their target genes. These genes, so-called "Wnt target genes", include protooncogenes, cell cycle regulators, stem cell markers, and negative feedback regulators of the Wnt pathway.
To date, there have been a number of proof-of-concept studies targeting the Wnt pathway for the treatment of cancer. Using Apc shRNA transgenic mice, Dow et al 4 showed that restoration of Apc could reestablish the control of crypt homeostasis in colorectal hyperproliferative polyps and cancer. The capacity for proliferation and self-renewal of CML cells carrying activated β-catenin was attenuated by the ectopic expression of Axin. 5 β-Catenin knockdown by RNAi significantly suppressed anchorage-independent growth and proliferation of liver cancer cells. 6 In addition, there is a growing body of evidence suggesting that Wnt/β-catenin signaling plays an essential role in the immune system. In metastatic melanoma, activation of the Wnt/β-catenin signaling pathway correlates with T cell exclusion. 7 Consistent with this view, multiomics analysis revealed that colorectal tumors with biallelic loss of the APC gene or nuclear accumulation of β-catenin protein were negatively correlated with tumor-infiltrating lymphocytes. 8 These reports suggested that activated Wnt signaling mediates cancer immune evasion and resistance to immunotherapies. Thus, blocking the Wnt pathway is an attractive approach to improve cancer immunotherapy. These data have prompted a search for chemical probes targeting this pathway (hereafter referred to as Wnt inhibitors). High-throughput screening (HTS) using a wide variety of assays has made significant contributions to the discovery of Wnt inhibitors. Indeed, HTS successfully identified small molecule compounds targeting porcupine and CREB-binding protein (CBP), and these compounds have already entered clinical trials. The establishment of a well-designed HTS system is crucial to identify Wnt inhibitor. Here, we comprehensively review Wnt inhibitors, and discuss the strategies involved in their identification.
| DE VELOPMENT OF REP ORTER A SSAYS OF THE WNT/β -C ATENIN S IG NALING PATHWAY
β-Catenin has been suggested to bind DNA mainly through the TCF/lymphoid enhancer-binding factor (LEF) transcription factors in mammals 9 and Drosophila. 10 The first observational evidence linking TCF/LEF directly to Wnt signaling resulted from yeast 2 hybrid screening using TCF1 11 or β-catenin 12 as bait. Another group also reported a physical interaction between β-catenin and LEF1. 13 In addition, these studies disclosed a responsible domain for the interaction, known as a β-catenin binding domain, in the amino terminus of the TCF/LEF protein. Deletion of the β-catenin binding domain produces a dominant negative form (dnTCF), which can outcompete with WT TCF/LEF for binding to the target sites. 14 
As
dnTCF7L2 abrogated the recruitment of β-catenin to the target chromatin regions in LS174T cells, TCF/LEF factors play a major role in the recruitment of β-catenin, at least in colorectal cancer cells. 9 However, in the absence of TCF/LEF factors, β-catenin is recruited through other transcription factors in HEK293T cells. 15 As TCF/LEF transcription factors act as major end-point mediators of this pathway, their DNA binding motif ( Figure 1A ) has been used as a faithful reporter for monitoring the Wnt/β-catenin signaling activity.
The TCF/LEF reporter plasmid originally incorporated 7 copies of approximately 30 bp of the CD3E enhancer region upstream of a minimal thymidine kinase promoter, and the chloramphenicol acetyltransferase gene (CAT) as a reporter (pMW56 7 ). As negative control, a mutant plasmid was prepared in which the WT TCF/LEF-binding motif AACAAAG was replaced by CCGCGGT (pMW56Sac 7 ). 16 TOPFlash, another synthetic TCF/LEF reporter plasmid containing tandemly repeated TCF motifs upstream of a minimal c-fos promoter and the versatile luciferase gene as a reporter, and FOPFlash, the negative control plasmid, were constructed ( Figure 1B ). 17, 18 As c-fos is a transcriptional target of Wnt/β-catenin signaling 19 and might affect the β-catenin-dependent transactivation, 20 thymidine kinase promoter-driven reporter plasmids have been used for this purpose. SuperTOPFlash, a plasmid with an increased number of TCF motifs, is currently available. 21 Although use of the transgenic TCF reporters to detect Wnt/β-catenin signaling in vivo remains controversial, 22 cell-based assays with TOPFlash or SuperTOPFlash are useful strategies for monitoring the activity of the Wnt signal and the evaluation of chemicals that could affect the activity.
Intriguingly, identification of genes negatively regulated by the β-catenin/TCF complex led to the development of a new reporter plasmid ( Figure 1B ). 23 This plasmid contains 8 copies of the promoter region of histidine ammonia-lyase (HAL) upstream of the luciferase gene. Unlike TOPFlash, the HAL reporter activity is inversely correlated with Wnt/β-catenin signaling activity ( Figure 1C ). The combination of HAL reporter and TOPFlash plasmids could serve as an effective screening system for the discovery of new Wnt inhibitors.
| APPLI C ATI ON OF REP ORTER A SSAY FOR HTS
Reporter assays using synthetic promoters containing multiple copies of a responsive element have been applied for HTS of small molecules and natural compounds affecting transcription and/or cellular signaling pathways. Because sensitivity, specificity, robustness, technical simplicity, and cost effectiveness are required for HTS, various strategies have been devised to meet the conditions. The Z′-factor has been widely accepted for quality control of the HTS assay. 24 An acceptable assay for HTS usually requires a Z′-value more than 0.5. Reportedly, the Z′-factor of a luciferase assay using HEK293 cells stably expressing TCF reporter and LiCl for the activation of the reporter was as high as 0.89. 25 Regarding the luciferase assay using fly cell-optimized TCF reporter and Drosophila imaginal disc-derived clone 8 cells, the Z′-factor was 0.77. 26 In the reciprocal assay, the Z′-factors for TOPFlash and the HAL promoter luciferase assays were 0.69 and 0.79, respectively. 23 Bioluminescent assays have been used in HTS as a major strategy, due to their high sensitivity, broad linearity, and robustness to chemicals. 27 Firefly luciferase (Photinus pyralis) and Renilla luciferase (Renilla reniformis) are commonly used as reporter genes. Firefly luciferase is F I G U R E 1 A, Position frequency matrix of the T-cell factor (TCF) motif was obtained from the JASPAR database (http://jaspar.gener eg.net). B, TOPFlash consists of tandemly repeated TCF motifs (Wnt response elements [WREs]) upstream of a minimal promoter that drives luciferase gene expression. FOPFlash has mutated motifs (mWREs) and is used to normalize the TOPFlash activity. HAL reporter was developed as a luciferase reporter driven by 8 copies of the promoter of histidine ammonia-lyase (HAL). Transcription factor (TF) that regulates the activity of HAL promoter is under investigation. C, These reporter plasmids were designed for monitoring the activity of Wnt/β-catenin pathway in cultured cells. When the pathway is inhibited, TOPFlash and HAL reporter activities are decreased and increased, respectively an enzyme of 61 kDa that catalyzes oxidation of a substrate (luciferin) in the presence of ATP and O 2 . This chemical reaction results in an emission of a yellow-green light with a spectral maximum of 560 nm. 27 Renilla luciferase, a 36 kDa enzyme, is often used as an internal control in the dual luciferase format. Genetically engineered luciferase genes have improved assay sensitivity by increasing intensity of the luminescent signal and enhanced response dynamics by reducing expression lifetime. NanoLuc luciferase has emerged as a potential alternative to firefly/Renilla luciferase for reporter gene assay because it showed an approximately 100-fold greater activity than that of firefly or Renilla luciferase. 28 Importantly, since NanoLuc is a relatively small protein (19 kDa) it could have less effect on nonspecific chemical binding.
| CELL-BA S ED REP ORTER A SSAY FOR SCREENING COMP OUNDS IN LIB R ARIE S
To date, cell-based HTS with TCF/LEF reporter plasmids have been frequently utilized for the identification of Wnt inhibitors. One of the greatest advantages in using secreted alkaline phosphate (SEAP) as a reporter is that there is no need to lyse the cells to measure its levels, because it is secreted directly into the culture medium. For example, screening of a library of 11 600 compounds using a SEAP reporter driven by Wnt response elements (WREs) identified FH535 and FH615 that suppressed Wnt/β-catenin signaling. 29 However, we might struggle with a high background in the assay because mammalian cells have endogenous alkaline phosphatase activity.
An alternative approach is the use of fluorescent proteins as a reporter. Waaler et al 30 Table 1 for more details and references). β-TrCP, β-transducin repeat containing E3 ubiquitin protein ligase; APC, APC regulator of WNT signaling pathway (adenomatous polyposis coli); CBP, CREB-binding protein; CK1, casein kinase-1; Dvl, Dishevelled segment polarity protein; GSK-3, glycogen synthase kinase-3; LEF, lymphoid enhancer binding factor; LRP, LDL receptor related protein; TCF7L2, transcription factor 7 like 2; TNKS, tankyrase Table 1 .
| WNT INHIB ITOR S D ISCOVERED BY HTS
The RO5 is a rule of thumb to evaluate drug-likeness, and defines 4 parameter ranges (molecular weight, 500 or less; calculated octanol/ water partition coefficient value, 5 or less; H-bond donors, 5 or less;
and H-bond acceptors, 10 or less).
| TANK YR A S E INHIB ITOR S
Using a cell-based SuperTOPFlash assay, Chen et al 33 Degradation of Axin is controlled through its poly-ADP-ribosylation (PARsylation) by TNKS. 34 Subsequently, IWR compounds turned out to be TNKS inhibitors ( Figure 3A ). Soon after, Huang et al 34 discovered another Axin stabilizer, XAV939 ( Figure 3B ), that directly binds TNKS and inhibits its PARsylation activity. An additional phenotypebased assay using zebrafish fin corroborated the inhibitory effect of Wnt activity by IWR and XAV939. Other TNKS inhibitors such as JW74, 30 WIKI4, 35 and K-756 36 have also been found by cell-based HTS.
| P ORCUPINE INHIB ITOR S
One of the possible therapeutic strategies for targeting Wntdriven cancers is to block the production of Wnt ligands. Porcupine (PORCN), a membrane-bound O-acyltransferase, was found to catalyze the palmitoylation of Wnt ligands, which is an essential step in the processing of Wnt into active ligands. 37 IWP-2, one of the inhibitors of Wnt production (IWPs), directly binds to PORCN, and inhibits the function of PORCN. 33 Another potent PORCN inhibitor, LGK974, was discovered by the screening of ~2 400 000 compounds using a TCF/LEF reporter assay, where Wnt3a-secreting cells were cocultured with mouse Leydig TM3 cells expressing SuperTOPFlash for the activation of the Wnt pathway. 38 An in vivo study reported that LGK974 diminished/eradicated tumors carrying RSPO fusions from the intestinal mucosa without effects on normal intestinal crypts. 39 In addition, LGK974 prevented proliferation and induced differentiation of RNF43-mutant pancreatic adenocarcinoma in xenograft models. 40 Currently, a phase I clinical trial (Clinicaltrials.gov ID NCT01351103) of LGK974 for patients with malignancies of histological origin carrying genetic alterations upstream in the Wnt signaling pathway (eg, RNF43 mutation or RSPO fusion) is underway.
| C A S EIN K INA S E-1α AC TI VATO R
To explore chemical probes that inhibit the turnover of Axin and promote the degradation of β-catenin, Thorne et al 41 
| INHIB ITOR S OF INTER AC TI ON B E T WEEN β -C ATENIN AND TCF
Activating mutations in β-catenin are frequently observed in several types of cancer, such as hepatocellular carcinoma, 43 where CTNNB1 mutations disrupt the phosphorylation and degradation of the β-catenin protein. In this case, inhibition of the upstream components is unable to induce the degradation of β-catenin. Thus, inhibition of the interaction of TCF/LEF with β-catenin or the coactivators is a rational and straightforward approach. To identify small molecules that disrupt the interaction, Lepourcelet et al 44 developed ELISA-based HTS using β-catenin and GST-fused TCF7L2 recombinant proteins. Consequently, they obtained 6 hits including PKF115-584 and CGP049090 from a library of 7000 natural compounds. Two other groups independently adopted AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay), a method for detecting intramolecular binding, for the discovery of inhibitors of the β-catenin-TCF interaction, and discovered LF3 and ZINC02092116. 45, 46 
TA B L E 1 Inhibitors of Wnt/β-catenin signaling discovered by high-throughput screening (HTS)
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Cell-based approaches have also discovered small molecule compounds iCRT, NC043, and niclosamide that target the β-catenin-TCF interaction. 26, 47, 48 For example, niclosamide was identified by HTS with 1280 pharmacologically active compounds in HCT116 cells expressing luciferase reporter driven by the promoter of the S1004A4 gene, a transcriptional target of the Wnt/β-catenin pathway. 47 Gonsalves et al identified iCRT3, iCRT4, and iCRT14 by screening 14 977 compounds using fly cell-optimized TCF reporter and Drosophila imaginal disc-derived clone 8 cells that had silenced dAxin expression for the activation of the reporter. 26 According to crystallographic analysis, the TCF7L2-binding region on β-catenin overlaps with the binding regions for APC and E-cadherin 49, 50 ; this might become a potential obstacle to develop selective Wnt inhibitor. Nevertheless, further characterization of iCRTs revealed that these compounds inhibited β-catenin-TCF interaction, whereas they had little or no effect on β-catenin-E-cadherin or β-catenin-α-catenin interaction. 26 In contrast, PKF222-815, PKF115-584, and CGP049090 blocked the interaction of β-catenin with TCF7L2, and unfavorably blocked its interaction with APC. 44 Increasing the specificity of inhibitors targeting the interaction of β-catenin and TCF remains a major challenge.
| INHIB ITOR S OF TR ANSCRIP TIONAL COAC TIVATOR S OF β -C ATENIN
Targeting the coactivators of β-catenin-dependent transcription is another strategy for the suppression of aberrant Wnt signaling. Molecular studies have identified a number of coactivators that interact with β-catenin (Wnt homepage, http://web.stanf ord.edu/group/ nusse lab/cgi-bin/wnt/prote in_inter actions). [51] [52] [53] High-throughput screening using TOPFlash assay in APC-mutated SW480 colorectal cancer cells identified ICG-001 that targets CBP, an interacting protein of β-catenin. 54 Recently, another E3 ubiquitin ligase, SHPRH that controls β-catenin stability, was also found to be targeted by a small molecule compound.
Screening of an FDA-approved drug library using SuperTOPFlash luciferase assay led to the discovery of axitinib, a known inhibitor of multireceptor tyrosine kinases, especially vascular endothelial growth factor receptors, 57 that stabilize SHPRH protein, thereby increasing the degradation of β-catenin. 58 Another screening of 800 compounds using TOPFlash assay identified CGK062 that promotes protein kinase Cα-mediated phosphorylation of β-catenin at Ser33/Ser37. 59 De Robertis et al 60 press the chemically induced eyeless phenotype in zebrafish embryos.
This phenotypic screening resulted in the discovery of GGTI-286, and they found that GGTI-286 reduces nuclear translocation of β-catenin through the inhibition of geranylgeranyltransferase (GGTase). It has been reported that GGTase catalyzes the addition of the geranylgeranyl group to Rac1 protein that is required for its membrane association and biological activity. 64 Rac1 activates JNK2 that in turn phosphorylates β-catenin at Ser191 and regulates its nuclear translocation, 65 suggesting that the reduced nuclear translocation of β-catenin by GGTI-286 might be associated with its interference with Rac1 protein.
A reciprocal reporter assay using TOPFlash coupled with HAL reporter led to a decrease in the number of false positives, and identified brefeldin A (BFA), a fungal metabolite, that suppresses the expression of β-catenin. 23 Although BFA was reported to inhibit protein secretion by blocking transport from the endoplasmic reticulum to the Golgi, 66 the precise mechanism(s) underlying the reduction in β-catenin by BFA needs further investigation.
| CON CLUS IONS
The discovery of Wnt inhibitors should provide potential benefits for cancer therapy. Although systematic unbiased screenings of the pathway have helped the identification of Wnt inhibitors, much of the underlying mechanisms remain to be elucidated. The target identification of small molecules from unbiased HTS is a challenge to be resolved.
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